Q1 Earnings Estimate for OTLK Issued By HC Wainwright

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Outlook Therapeutics in a research note issued on Tuesday, February 18th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright currently has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Outlook Therapeutics' current full-year earnings is ($2.27) per share. HC Wainwright also issued estimates for Outlook Therapeutics' Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.16) EPS and FY2029 earnings at $3.24 EPS.

Several other brokerages also recently weighed in on OTLK. BTIG Research cut their price target on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, November 29th. Guggenheim reaffirmed a "buy" rating and issued a $12.00 target price on shares of Outlook Therapeutics in a report on Friday, January 17th. Finally, Chardan Capital reissued a "neutral" rating and issued a $3.00 price objective on shares of Outlook Therapeutics in a research report on Tuesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $12.00.

Outlook Therapeutics Trading Down 4.9 %

OTLK traded down $0.08 on Wednesday, hitting $1.56. The company had a trading volume of 753,835 shares, compared to its average volume of 613,068. The company's fifty day moving average price is $1.89 and its 200 day moving average price is $4.33. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85. The firm has a market cap of $49.95 million, a P/E ratio of -0.21 and a beta of 0.58.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its earnings results on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04).

Institutional Investors Weigh In On Outlook Therapeutics

Several institutional investors have recently added to or reduced their stakes in OTLK. Russell Investments Group Ltd. increased its stake in Outlook Therapeutics by 34,936.7% in the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company's stock valued at $32,000 after purchasing an additional 17,119 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of Outlook Therapeutics in the 4th quarter valued at $48,000. Jane Street Group LLC grew its position in shares of Outlook Therapeutics by 133.9% in the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock valued at $50,000 after buying an additional 15,008 shares during the last quarter. Christensen King & Associates Investment Services Inc. purchased a new position in shares of Outlook Therapeutics in the 3rd quarter valued at $55,000. Finally, Bank of New York Mellon Corp raised its stake in Outlook Therapeutics by 44.8% during the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company's stock worth $56,000 after acquiring an additional 9,211 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company's stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.